Table 1.
Human studies involving IVA and Drug-Free IVA in POI and POR patients.
| Author | Ref. | Procedure type | No. of patients | Inclusion criteria | Follicle development/Total | Pregnancies/Total | Live birth: total |
|---|---|---|---|---|---|---|---|
| Kawamura et al., 2013; Suzuki et al., 2015 | (10, 11) | IVA | 37 | POI | 9/37 | 3/37 | 2:37 |
| Zhai et al., 2016 | (43) | IVA | 14 | POI | 6/14 | 1/14 | 1:14 |
| Pellicer et al., 2017** | – | OFFA (Drug-Free IVA) | 14 | POI | – | 3/14 | 3:14 |
| Zhang et al., 2018 | (46) | Biopsy/Scratch | 80 | POI | 11/80 | 1/80 | 1:80 |
| Fàbregues et al., 2018; Ferreri et al., 2020 | (13, 14) | Drug-Free IVA | 14 | POI | 7/14 | 4/14 | 4:14 |
| Mahajan et al., 2019 | (45) | Drug-Free IVA | 1 | POI | 1/1 | – | – |
| Kawamura et al., 2020 | (15) | Drug-Free IVA | 11 | POR | 9/11* | 5/11 | 2:11 2 ongoing 1 miscarriage |
*Patients increased AFC.
**Unofficial data are from conference presentations of stated scientist.
POI, Primary ovarian insufficiency; IVA, in vitro activation; OFFA, Ovarian fragmentation for folicular activation.